Carlsmed, Inc. (CARL) vs DiaMedica Therapeutics Inc. (DMAC)
A side-by-side comparison of Carlsmed, Inc. and DiaMedica Therapeutics Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
CARL
Carlsmed, Inc.
$15.30HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT
DMAC
DiaMedica Therapeutics Inc.
$8.42HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT
Total return — CARL vs DMAC
growth of $100 · dividends reinvested · last 1yCARL +5.5% (+5.5%/yr)DMAC +101.4% (+101.4%/yr)DMAC compounded faster over this window
CARL DMAC
CARL vs DMAC: by the numbers
- •DMAC is the larger company ($454M vs $416M market cap).
- •Both run net losses; DMAC's is the smaller (0.00% vs -57.42% net margin).
Metrics side by side
Valuation
| Metric | CARL | DMAC |
|---|---|---|
| P/S ratio | 6.57 | N/A |
| P/B ratio | 4.94 | 11.83 |
Profitability
| Metric | CARL | DMAC |
|---|---|---|
| Gross margin | 76.63% | 0.00% |
| Operating margin | -61.09% | 0.00% |
| Net margin | -57.42% | 0.00% |
| ROE | -43.14% | -97.92% |
| ROIC | -36.54% | -100.87% |
Growth (annualized)
| Metric | CARL | DMAC |
|---|---|---|
| Total return CAGR (5Y) | N/A | 16.41% |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.